600529 Shandong Pharmaceutical Glass
- 26.17
- -0.03-0.11%
Shandong Pharmaceutical Glass News
The Total Return for Shandong Pharmaceutical GlassLtd (SHSE:600529) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying the right stocks can give your wealth a significant boost. For example, the Shand
Shandong Pharmaceutical (600529.SH): List of goods subject to new tariffs imposed by the US in May, not involving the types of products exported by the company to the US
Gelonghui, May 28 | Shandong Pharmaceutical (600529.SH) said on the investor interactive platform that the list of goods subject to new tariffs imposed by the US in May 2024 did not cover the types of products the company exported to the US.
Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shandong Pharmaceutical GlassLtd fair value estimate is CN¥24.29 With CN¥28.73 share price, Shandong Pharmaceutical GlassLtd appears to be tr
Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a sad week for Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529), who've watched their investment drop 11% to CN¥28.48 in the week since the company reported its quarterly result. The
Shandong Pharmaceutical (600529.SH): Net profit of 221 million yuan in the first quarter increased 32.59% year-on-year
Gelonghui, April 22丨Shandong Pharmaceutical (600529.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,267 million yuan, up 2.50% year on year; net profit attributable to shareholders of listed companies was 221 million yuan, up 32.59% year on year; after deducting non-net profit of 210 million yuan, up 36.14% year on year; basic earnings per share were 0.33 yuan.
Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529) Investors Are Less Pessimistic Than Expected
It's not a stretch to say that Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) price-to-earnings (or "P/E") ratio of 28.6x right now seems quite "middle-of-the-road" compared to the market in Ch
Is Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Shandong Pharmaceutical GlassLtd (SHSE:600529) has had a great run on the share market with its stock up by a significant 14% over the last three months. As most would know, fundamentals are what us
Returns On Capital At Shandong Pharmaceutical GlassLtd (SHSE:600529) Have Stalled
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and th
Shandong Pharmaceutical Glass (600529.SH): Currently, the yield rate of borosilicate glass tubes is about 60%
Gelonghui, Feb. 19: Shandong Pharmaceutical (600529.SH) said on the investor interactive platform that the company currently has a yield of about 60% of borosilicate glass tubes, about 70% of mass production. Currently, the company's borosilicate glass tube self-use rate is over 50%.
Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529) Surges 11%; Retail Investors Who Own 57% Shares Profited Along With Institutions
Key Insights The considerable ownership by retail investors in Shandong Pharmaceutical GlassLtd indicates that they collectively have a greater say in management and business strategy 41% of the bus
Shandong Pharmaceutical Glass (600529.SH): Currently, the self-use rate of borosilicate glass tubes in the company is above 50%
Gelonghui, January 26丨Shandong Pharmaceutical (600529.SH) recently said during a survey receiving institutional investors that the company currently has an electric furnace that produces borosilicate glass tubes. The yield rate of medium borosilicate glass tubes is about 60%, and mass production is about 70%. Currently, the company's borosilicate glass tube self-use rate is over 50%.
Shandong Pharmaceutical (600529.SH): The company's foreign trade growth rate was obvious in '23, and foreign trade revenue accounted for about 1/3 of the company's total revenue
Gelonghui, January 26丨Shandong Pharmaceutical (600529.SH) recently said during a survey receiving institutional investors that the company's foreign trade growth rate was obvious in '23. Foreign trade revenue accounted for about 1/3 of the company's total revenue. The growth point mainly comes from the volume of brown bottles and ordinary soda-calcium molded bottles.
Shandong Pharmaceutical Glass (600529.SH): Currently, the company's raw materials are mainly quartz sand, soda ash, and borax
Gelonghui, January 26丨Shandong Pharmaceutical (600529.SH) recently said during a survey reception from institutional investors that the company's raw materials are currently mainly quartz sand, soda ash, and borax. Prices of soda ash and borax were still at historically high levels in '23, and soda ash has declined compared to '22. The price of quartz sand is relatively stable. Energy side: Prices of coal and natural gas have declined slightly from '22, but they are still high compared to '21.
Shandong Pharmaceutical Glass (600529.SH): In 2024, we will continue to push forward the commissioning schedule of the fund-raising project to expand the production capacity of the borosilicate pharmaceutical glass business in due course
Gelonghui, January 26丨Shandong Pharmaceutical (600529.SH) recently said during a survey receiving institutional investors that, driven by consistent evaluations and collection, borosilicate molded bottles have maintained a relatively rapid growth rate for 23 years. Looking at the previous three quarters, the contribution rate of borosilicate molded bottles on the revenue side and profit side continued to expand. In 2024, the company will continue to push forward the commissioning of the fund-raising project and expand the production capacity of the borosilicate medicinal glass business in due course according to market demand. In '23, the company's brown bottles and daily chemical food bottles also grew well, contributing greatly to the company's overall revenue.
Shandong Pharmaceutical GlassLtd's (SHSE:600529) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make significant gains if you buy good quality businesses at the right price. For ex
Shandong Pharmaceutical (600529.SH): The company once again passed the high-tech enterprise certification
Gelonghui, January 12: Shandong Pharmaceutical (600529.SH) announced that it recently received the “High-tech Enterprise Certificate” jointly issued by the Shandong Provincial Department of Science and Technology, the Shandong Provincial Department of Finance, and the Shandong Provincial Taxation Bureau of the State Administration of Taxation. This high-tech enterprise certification is a re-certification after the validity period of the original high-tech enterprise certificate expires, and will not have a significant impact on the company's current business performance. Investors are kindly requested to pay attention to investment risks.
Return Trends At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Appealing
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) an
Are Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
With its stock down 9.0% over the past month, it is easy to disregard Shandong Pharmaceutical GlassLtd (SHSE:600529). However, the company's fundamentals look pretty decent, and long-term financials
Guolian Securities: Q3 Building Materials Sector Performance Continues to Differentiate, Suggests Focus on Two Aspects of Layout
The overall performance of building materials companies in 23Q3 reflects that macro-infrastructure/real estate demand is still weak during the phase.
[Instant Analysis of BT Financial Report] Shandong Pharmaceutical Glass 2023 Third Quarter Report: Significant increase in net profit and impressive performance
Announcement time of this financial report: 2023-10-18 16:47:00 Shandong Pharmaceutical Glass (stock code: 600529) is a company that plays an important role in the pharmaceutical packaging materials (pharmaceutical packaging materials) industry. It is mainly engaged in the manufacture of pharmaceutical auxiliary materials and packaging materials. Its products also belong to the manufacture of glass packaging containers in the non-metallic mineral products industry. According to its 2023 three-quarter report, we can see the company's performance in various financial indicators. First, we're looking at changes in net worth. Net assets at the end of the reporting period were $7.375 billion, up from $6.962 billion at the end of the previous year
Analysis
Price Target
No Data
